Testosterone and prostate cancer: An historical perspective on a modern myth

被引:185
作者
Morgentaler, Abraham [1 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA
关键词
testosterone; prostate cancer; hypogonadism; castration; history; risk; testosterone replacement therapy;
D O I
10.1016/j.eururo.2006.06.034
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To review the historical origins and current evidence for the belief that testosterone (T) causes prostate cancer (pCA) growth. Methods: Review of the historical literature regarding T administration and pCA, as well as more recent studies investigating the relationship of T and pCA. Results: In 1941 Huggins and Hodges reported that marked reductions in T by castration or estrogen treatment caused metastatic pCA to regress, and administration of exogenous T caused pCA to grow. Remarkably, this latter conclusion was based on results from only one patient. Multiple subsequent reports revealed no pCA progression with T administration, and some men even experienced subjective improvement, such as resolution of bone pain. More recent data have shown no apparent increase in pCA rates in clinical trials of T supplementation in normal men or men at increased risk for pCA, no relationship of pCA risk with serum T levels in multiple longitudinal studies, and no reduced risk of pCA in men with low T. The apparent paradox in which castration causes pCA to regress yet higher T fails to cause pCA to grow is resolved by a saturation model, in which maximal stimulation of pCA is reached at relatively low levels of T. Conclusions: This historical perspective reveals that there is not now-nor has there ever been-a scientific basis for the belief that T causes pCA to grow. Discarding this modern myth will allow exploration of alternative hypotheses regarding the relationship of T and pCA that may be clinically and scientifically rewarding. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:935 / 939
页数:5
相关论文
共 37 条
[1]   Prevention of prostate cancer by androgens:: Experimental paradox or clinical reality [J].
Algarté-Génin, M ;
Cussenot, O ;
Costa, P .
EUROPEAN UROLOGY, 2004, 46 (03) :285-294
[2]   Testosterone replacement therapy and the risk of prostate cancer: a perspective view [J].
Barqawi, AB ;
Crawford, ED .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (05) :462-463
[3]  
BARRETTCONNOR E, 1990, CANCER RES, V50, P169
[4]  
BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341
[5]  
Bhasin S, 2003, J ANDROL, V24, P299
[6]   Testosterone dose-response relationships in healthy young men [J].
Bhasin, S ;
Woodhouse, L ;
Casaburi, R ;
Singh, AB ;
Bhasin, D ;
Berman, N ;
Chen, XH ;
Yarasheski, KE ;
Magliano, L ;
Dzekov, C ;
Dzekov, J ;
Bross, R ;
Phillips, J ;
Sinha-Hikim, I ;
Shen, RQ ;
Storer, TW .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (06) :E1172-E1181
[7]   PROSTATIC CANCER - FURTHER INVESTIGATION OF HORMONAL RELATIONSHIPS [J].
BRENDLER, H ;
CHASE, WE ;
SCOTT, WW .
ARCHIVES OF SURGERY, 1950, 61 (03) :433-440
[8]   Is the flare phenomenon clinically significant? [J].
Bubley, GJ .
UROLOGY, 2001, 58 (2A) :5-9
[9]  
Chen C, 2003, CANCER EPIDEM BIOMAR, V12, P1410
[10]   Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men [J].
Cooper, CS ;
Perry, PJ ;
Sparks, AET ;
MacIndoe, JH ;
Yates, WR ;
Williams, RD .
JOURNAL OF UROLOGY, 1998, 159 (02) :441-443